Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of July 2025 for Radiopharm Theranostics Limited, a foreign private issuer headquartered in Carlton South, Victoria, Australia. The report serves to disclose a specific corporate announcement made to the Australian Securities Exchange on July 22, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of Dr. Oliver Sartor to the Company's Scientific Advisory Board. No financial or operational changes relative to a prior comparable period are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document strictly reports the appointment of Dr. Sartor and includes a standard disclaimer that the report is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Dr. Oliver Sartor has been appointed to the Scientific Advisory Board.
- The announcement was published on the Australian Securities Exchange on July 22, 2025.
- This Form 6-K does not include financial data or operational results.
- The report is signed by Phillip Hains, Company Secretary.